Medullary Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

  • ID: 4426652
  • Report
  • Region: Global
  • 88 Pages
  • VPA Research
1 of 5
The Report Focuses on Drugs and Therapies Being Evaluated for Medullary Thyroid Cancer Treatment in Active Clinical Development Phases Including Phase 1, Phase 2, Phase 3 and Phase 4 Clinical Trials

FEATURED COMPANIES

  • Bayer
  • Exelixis
  • Genzyme Europe B.V.
  • Loxo Oncology, Inc.
  • Sanofi
  • Stemcentrx
  • MORE

Medullary Thyroid Cancer clinical trials report from provides comprehensive analysis and trends in global Medullary Thyroid Cancer disease clinical trials. The research work analyzes the evolution of Medullary Thyroid Cancer clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Medullary Thyroid Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Medullary Thyroid Cancer clinical trials.

Major drugs under development in Medullary Thyroid Cancer are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report:

  • Number of Medullary Thyroid Cancer clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Medullary Thyroid Cancer
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Medullary Thyroid Cancer clinical trials worldwide are listed

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Thyroid Cancer is the cancer type originating in Thyroid gland. Though specific causes are not determined, the cancer occurs when thyroid cells undergo mutations, making cells to increase rapidly in count and size, forming tumors.

Types:

Thyroid Cancer is categorized into three main types:

  • Differentiated Thyroid Cancer
    •  Follicular
    •  Papillary
    •  Hurthle
  • Medullary Thyroid Cancer
    •  Sporadic
    •  Familial
  • Anaplastic Thyroid Cancer

Stages:

  • Stage I - Tumor less than 2 cm
  • Stage II - Tumor between 2 cm and 4 cm
  • Stage III - Tumor more than 4 cm, or grown slightly beyond thyroid
  • Stage IVa- Tumor expands into nearby neck tissues/ some lymph nodes/ upper chest
  • Stage IVb- Tumor expands to spine/ blood vessels
  • Stage IVC: Tumor might be spread to distant sites of body

Companies conducting Medullary Thyroid Cancer trials include:

  • Genzyme Europe B.V.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
  • Loxo Oncology, Inc.
  • Blueprint Medicines Corporation
  • Exelixis
  • Sanofi
  • Stemcentrx
  • Bayer
  • Hutchison Medipharma Limited
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer
  • Exelixis
  • Genzyme Europe B.V.
  • Loxo Oncology, Inc.
  • Sanofi
  • Stemcentrx
  • MORE

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Conducted in 2017
2.2.2 Average Enrolment by Country, 2010 - 2017
2.2.3 Prominent Companies in Global Medullary Thyroid Cancer Trials, 2010 - 2017
2.2.4 Inverse Relation between TSH levels and papillary thyroid cancer Observed
2.2.5 Primary users with regular Thyroxine found to have increased risk of thyroid cancer
2.2.6 Radioactive Iodine use as follow-up treatment for Thyroid Cancer to Increase AML risk

3 Medullary Thyroid Cancer Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Medullary Thyroid Cancer
3.2 Medullary Thyroid Cancer Product Snapshots
3.2.1 Medullary Thyroid Cancer Drug Profiles

4 Global Medullary Thyroid Cancer Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010 - 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010 - 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010 - 2017
4.4 Subjects Recruited by Region, 2010 - 2017
4.5 Clinical Trials by Year, 2010 - 2017
4.6 Subjects Recruited by Year, 2010 - 2017
4.7 Clinical Trials by Development Phase, 2010 - 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010 - 2017
4.9 Clinical Trials by Status, 2010 - 2017
4.10 Subjects Recruited by Trial Status, 2010 - 2017
4.11 Clinical Trials by Sponsor Type, 2010 - 2017
4.12 Subjects Recruited by Sponsor Type, 2010 - 2017
4.13 Clinical Trials by Economy Type, 2010 - 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010 - 2017

5 Europe Medullary Thyroid Cancer Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010 - 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010 - 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010 - 2017
5.4 Europe, Clinical Trials by Development Phase, 2010 - 2017
5.5 Europe, Clinical Trials by Trial Status, 2010 - 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010 - 2017

6 North America Medullary Thyroid Cancer Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in North America, 2010 - 2017
6.1.1 North America, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in North America, 2010 - 2017
6.2.1 North America, Total Enrolment by Country
6.3 North America, Clinical Trials by Year, 2010 - 2017
6.4 North America, Clinical Trials by Development Phase, 2010 - 2017
6.5 North America, Clinical Trials by Trial Status, 2010 - 2017
6.6 North America, Clinical Trials by Sponsor Type, 2010 - 2017

7 Western Pacific Medullary Thyroid Cancer Clinical Trial Research Trends
7.1 Clinical Trials by Top Countries in Western Pacific, 2010 - 2017
7.1.1 Western Pacific, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Western Pacific, 2010 - 2017
7.2.1 Western Pacific, Total Enrolment by Country
7.3 Western Pacific, Clinical Trials by Year, 2010 - 2017
7.4 Western Pacific, Clinical Trials by Development Phase, 2010 - 2017
7.5 Western Pacific, Clinical Trials by Trial Status, 2010 - 2017
7.6 Western Pacific, Clinical Trials by Sponsor Type, 2010 - 2017

8 South East Asia Medullary Thyroid Cancer Clinical Trial Research Trends
8.1 Clinical Trials by Top Countries in South East Asia, 2010 - 2017

9 South and Central America Medullary Thyroid Cancer Clinical Trial Research Trends

10 Recent Clinical Trials - Snapshots
10.1 Medullary Thyroid Cancer Trial Snapshots - 2017
10.2 Medullary Thyroid Cancer Trial Snapshots - 2016
10.3 Medullary Thyroid Cancer Trial Snapshots - 2015
10.4 Medullary Thyroid Cancer Trial Snapshots - 2014
10.5 Medullary Thyroid Cancer Trial Snapshots - 2013
10.6 Medullary Thyroid Cancer Trial Snapshots - 2012
10.7 Medullary Thyroid Cancer Trial Snapshots - 2011
10.8 Medullary Thyroid Cancer Trial Snapshots - 2010

11 Appendix
11.1 About the Publisher
11.2 Sources and Research Methodology

List of Figures:
Figure 1: Thyroid Cancer - Average Enrolment by Country, 2010 - 2017
Figure 2: Medullary Thyroid Cancer - Country wise Clinical Trials, 2010 - 2017
Figure 3: Medullary Thyroid Cancer - Country wise Ongoing Trial Sites, 2010 - 2017
Figure 4: Medullary Thyroid Cancer - Country wise Subjects Recruited, 2010 - 2017
Figure 5: Global Medullary Thyroid Cancer Clinical Trials Participation Share by Region, 2010 - 2017
Figure 6: Global Medullary Thyroid Cancer Subjects Recruited by Region, 2010 - 2017
Figure 7: Global Medullary Thyroid Cancer Clinical Trials by Year, 2010 - 2017
Figure 8: Global Medullary Thyroid Cancer Subjects Recruited by Year, 2010 - 2017
Figure 9: Global Medullary Thyroid Cancer Trials by Phase, 2010 - 2017
Figure 10: Global Medullary Thyroid Cancer - Subjects Recruited by Phase, 2010 - 2017
Figure 11: Global Medullary Thyroid Cancer - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 12: Global Medullary Thyroid Cancer - Subjects Recruited by Trial Status, 2010 - 2017
Figure 13: Global Medullary Thyroid Cancer - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 14: Global Medullary Thyroid Cancer - Subjects Recruited by Trial Status, 2010 - 2017
Figure 15: Global Medullary Thyroid Cancer - Clinical Trials by Type of Economy, 2010 - 2017
Figure 16: Europe Medullary Thyroid Cancer - Country wise Clinical Trials, 2010 - 2017
Figure 17: Europe Medullary Thyroid Cancer - Country wise Subjects Recruited, 2010 - 2017
Figure 18: Europe Medullary Thyroid Cancer - Year wise Clinical Trials, 2010 - 2017
Figure 19: Europe Medullary Thyroid Cancer Trials by Phase, 2010 - 2017
Figure 20: Europe Medullary Thyroid Cancer - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 21: Europe Medullary Thyroid Cancer - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 22: North America Medullary Thyroid Cancer - Country wise Clinical Trials, 2010 - 2017
Figure 23: North America Medullary Thyroid Cancer - Country wise Subjects Recruited, 2010 - 2017
Figure 24: North America Medullary Thyroid Cancer - Year wise Clinical Trials, 2010 - 2017
Figure 25: North America Medullary Thyroid Cancer Trials by Phase, 2010 - 2017
Figure 26: North America Medullary Thyroid Cancer - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 27: North America Medullary Thyroid Cancer - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 28: Western Pacific Medullary Thyroid Cancer - Country wise Clinical Trials, 2010 - 2017
Figure 29: Western Pacific Medullary Thyroid Cancer - Country wise Subjects Recruited, 2010 - 2017
Figure 30: Western Pacific Medullary Thyroid Cancer - Year wise Clinical Trials, 2010 - 2017
Figure 31: Western Pacific Medullary Thyroid Cancer Trials by Phase, 2010 - 2017
Figure 32: Western Pacific Medullary Thyroid Cancer - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 33: Western Pacific Medullary Thyroid Cancer - Clinical Trials by Sponsor Type, 2010 - 2017

List of Tables:
Table 1: Medullary Thyroid Cancer Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Medullary Thyroid Cancer Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target (2)
Table 3: Medullary Thyroid Cancer Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target (3)
Table 4: Medullary Thyroid Cancer Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target (4)
Table 5: Medullary Thyroid Cancer - Region wise Clinical Trials, 2010 - 2017
Table 6: Medullary Thyroid Cancer - Region wise Subjects Recruited, 2010 - 2017
Table 7: Global Medullary Thyroid Cancer - Clinical Trials and Subjects by Trial Type, 2010 - 2017
Table 8: Medullary Thyroid Cancer Trial Snapshots - 2017
Table 9: Medullary Thyroid Cancer Trial Snapshots - 2017
Table 10: Medullary Thyroid Cancer Trial Snapshots - 2017
Table 11: Medullary Thyroid Cancer Trial Snapshots - 2017
Table 12: Medullary Thyroid Cancer Trial Snapshots - 2017
Table 13: Medullary Thyroid Cancer Trial Snapshots - 2016
Table 14: Medullary Thyroid Cancer Trial Snapshots - 2016
Table 15: Medullary Thyroid Cancer Trial Snapshots - 2016
Table 16: Medullary Thyroid Cancer Trial Snapshots - 2016
Table 17: Medullary Thyroid Cancer Trial Snapshots - 2015
Table 18: Medullary Thyroid Cancer Trial Snapshots - 2015
Table 19: Medullary Thyroid Cancer Trial Snapshots - 2015
Table 20: Medullary Thyroid Cancer Trial Snapshots - 2014
Table 21: Medullary Thyroid Cancer Trial Snapshots - 2014
Table 22: Medullary Thyroid Cancer Trial Snapshots - 2014
Table 23: Medullary Thyroid Cancer Trial Snapshots - 2014
Table 24: Medullary Thyroid Cancer Trial Snapshots - 2014
Table 25: Medullary Thyroid Cancer Trial Snapshots - 2013
Table 26: Medullary Thyroid Cancer Trial Snapshots - 2013
Table 27: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 28: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 29: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 30: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 31: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 32: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 33: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 34: Medullary Thyroid Cancer Trial Snapshots - 2012
Table 35: Medullary Thyroid Cancer Trial Snapshots - 2011
Table 36: Medullary Thyroid Cancer Trial Snapshots - 2010
Table 37: Medullary Thyroid Cancer Trial Snapshots - 2010
Table 38: Medullary Thyroid Cancer Trial Snapshots - 2010
Table 39: Medullary Thyroid Cancer Trial Snapshots - 2010
Table 40: Medullary Thyroid Cancer Trial Snapshots - 2010 "

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer
  • Blueprint Medicines Corporation
  • Exelixis
  • Genzyme Europe B.V.
  • Hutchison Medipharma Limited
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
  • Loxo Oncology, Inc.
  • Sanofi
  • Stemcentrx
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll